ROVIELLO, GIANDOMENICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.033
AS - Asia 12.811
EU - Europa 9.210
SA - Sud America 2.491
AF - Africa 349
OC - Oceania 150
Continente sconosciuto - Info sul continente non disponibili 6
Totale 42.050
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.772
RU - Federazione Russa 4.066
CN - Cina 3.862
SG - Singapore 3.309
BR - Brasile 2.008
HK - Hong Kong 1.537
IT - Italia 1.495
VN - Vietnam 1.426
KR - Corea 1.264
PL - Polonia 871
IE - Irlanda 744
FR - Francia 430
SE - Svezia 329
IN - India 316
FI - Finlandia 306
DE - Germania 290
BD - Bangladesh 247
ID - Indonesia 208
GB - Regno Unito 192
AR - Argentina 181
AU - Australia 144
JP - Giappone 115
CA - Canada 107
EC - Ecuador 105
JO - Giordania 103
NG - Nigeria 103
ES - Italia 98
TR - Turchia 86
NL - Olanda 85
MX - Messico 74
IQ - Iraq 69
CH - Svizzera 68
ZA - Sudafrica 55
AT - Austria 53
UA - Ucraina 48
CO - Colombia 41
CI - Costa d'Avorio 40
PK - Pakistan 37
AE - Emirati Arabi Uniti 36
CL - Cile 34
BJ - Benin 33
PY - Paraguay 33
VE - Venezuela 31
EG - Egitto 30
MA - Marocco 30
PE - Perù 27
UZ - Uzbekistan 26
LU - Lussemburgo 19
PH - Filippine 19
TH - Thailandia 19
UY - Uruguay 19
CZ - Repubblica Ceca 17
SA - Arabia Saudita 17
BE - Belgio 15
KZ - Kazakistan 15
TN - Tunisia 15
DO - Repubblica Dominicana 14
KE - Kenya 14
MY - Malesia 14
RS - Serbia 14
HN - Honduras 13
AZ - Azerbaigian 12
PT - Portogallo 12
BO - Bolivia 11
NP - Nepal 10
JM - Giamaica 9
NI - Nicaragua 9
TT - Trinidad e Tobago 9
DZ - Algeria 8
GR - Grecia 8
LT - Lituania 8
AL - Albania 7
IL - Israele 7
BB - Barbados 6
CR - Costa Rica 6
LB - Libano 6
OM - Oman 6
BY - Bielorussia 5
GT - Guatemala 5
KG - Kirghizistan 5
NO - Norvegia 5
SN - Senegal 5
SY - Repubblica araba siriana 5
BH - Bahrain 4
GE - Georgia 4
SV - El Salvador 4
TW - Taiwan 4
XK - ???statistics.table.value.countryCode.XK??? 4
CY - Cipro 3
ET - Etiopia 3
HU - Ungheria 3
IR - Iran 3
KH - Cambogia 3
KW - Kuwait 3
LI - Liechtenstein 3
LV - Lettonia 3
MD - Moldavia 3
NZ - Nuova Zelanda 3
PA - Panama 3
RO - Romania 3
Totale 42.008
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.550
Singapore 2.620
Ashburn 2.386
Fairfield 1.596
Hefei 1.383
Hong Kong 1.320
Seoul 1.263
Warsaw 863
Dublin 739
Woodbridge 735
Seattle 687
San Jose 598
Houston 592
Cambridge 565
Wilmington 527
Beijing 517
Ho Chi Minh City 473
Lawrence 334
Altamura 332
Moscow 311
The Dalles 303
Hanoi 296
Council Bluffs 292
Los Angeles 278
Lauterbourg 276
Buffalo 216
Florence 206
Ann Arbor 203
Chandler 199
New York 197
Helsinki 183
Princeton 171
Boston 170
São Paulo 164
Dallas 162
Kent 150
Jakarta 142
Clifton 133
Melbourne 130
Mumbai 120
Munich 109
Abuja 101
Rome 99
Shanghai 97
Milan 89
Tokyo 87
San Diego 82
Bengaluru 78
Lappeenranta 76
Haiphong 74
London 65
Paris 60
Barcelona 57
Bern 57
Frankfurt am Main 57
Boardman 54
Da Nang 54
Rio de Janeiro 54
Chicago 48
Redondo Beach 47
Dong Ket 46
Guangzhou 44
Orem 44
Brasília 43
Vienna 42
Bremen 41
Medford 40
Abidjan 39
Curitiba 39
Guayaquil 39
Norwalk 37
Turku 37
Toronto 34
Biên Hòa 33
Cotonou 33
Shenzhen 33
Johannesburg 31
Porto Alegre 31
West Jordan 31
Belo Horizonte 30
Falls Church 29
Quito 29
Buenos Aires 27
Hải Dương 27
Ninh Bình 27
Brooklyn 26
Denver 26
Phoenix 26
Montreal 25
Pune 25
Yubileyny 25
Baghdad 24
Salt Lake City 24
Stockholm 23
Tianjin 23
Tashkent 22
Adana 21
Atlanta 21
Campinas 21
Arezzo 20
Totale 28.065
Salva come PNG Salva come JPEG
Nome #
Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience 296
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions 252
Darolutamide in hormone-sensitive and castration-resistant prostate cancer 252
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer 246
Gender matters. Sex-related differences in immunotherapy outcome in patients with non-small cell lung cancer 231
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience 221
A husband and a wife with simultaneous presentation of glioblastoma multiforme: a case report 215
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score 212
Hypoxia-related biological markers as predictors of epirubicinbased treatment responsiveness and resistance in locally advanced breast cancer 210
Adjuvant Therapy for Renal Cell Carcinoma: Hype or Hope? 206
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma 205
Is there still a place for docetaxel rechallenge in prostate cancer? 204
Current status and future perspectives in HER2 positive advanced gastric cancer 197
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study 196
An exceptional overall survival using bevacizumab beyond progression in a patient with Non-small cell lung cancer 196
Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? 195
Isolated Testicular Metastasis from Prostate Cancer 191
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 189
Low-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer 188
Effects of abiraterone acetate on chronic kidney disease in 2 patients with metastatic castration-resistant prostate cancer 187
Gender and Advanced Urothelial Cancer: Outcome, Efficacy and Toxicity following Chemotherapy 185
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination with Eribulin in Triple-Negative Breast Cancers 182
Ntrk gene fusion detection in atypical spitz tumors 181
A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin 180
Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors 179
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 178
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience 178
The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015 177
Adjuvant treatment for EGFR-mutated non-small cell lung cancer: Do we have a major breakthrough? 177
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 177
Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer? 177
PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients 176
DNA repair deficiency as circulating biomarker in prostate cancer 175
A Phase II study of olaparib in breast cancer patients: Biological evaluation from a 'window of opportunity' trial 175
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy 175
Five years of stable disease with maintenance therapy using bevacizumab and tamoxifen in a patient with metastatic breast cancer 172
Inflammation in Urological Malignancies: The Silent Killer 171
Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now? 171
Immune checkpoint inhibitor-induced neurologic toxicity: a case report and literature review 169
Robotic approach with neoadjuvant chemotherapy in adult Wilms' tumor: A feasibility study report and a systematic review of the literature 168
Angiogenesis inhibitors in gastric and gastroesophageal junction cancer 168
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer 168
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies 167
Maintenance treatment with oral cyclophosphamide and bevacizumab in patients with recurrent epithelial ovarian cancer 167
Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033 167
Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223 166
Gender and cystectomy for bladder cancer: A high-volume tertiary urologic care center experience 165
Perineural invasion score system and clinical outcomes in resected pancreatic cancer patients 164
Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI 164
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice 164
NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities 163
Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment 163
Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma 162
Advances in systemic therapy for metastatic breast cancer: future perspectives 161
Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience 161
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25) 160
Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer 160
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival 160
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer 159
Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors 158
Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study 158
Targeting z-Crystallin by aspirin restores the sensitivity to cisplatin in resistant A2780 ovarian cancer cells 157
Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged ≥ 75 years with impaired performance status 157
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? 156
Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 155
Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights 155
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer 155
Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer 155
Immune checkpoint inhibitors in urothelial bladder cancer: State of the art and future perspectives 155
Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma 155
Immune checkpoint inhibitors in pre-treated gastric cancer patients: Results from a literature-based meta-analysis 154
Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer 153
The distinctive nature of adenocarcinoma of the lung 153
Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate 153
Liquid biopsy in colorectal cancer: No longer young, but not yet old 152
CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab 152
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 152
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 150
Bevacizumab in small cell lung cancer 150
ALTERTASTE: improving food pleasure and intake of oncology patients receiving chemotherapy 150
PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy 149
Prognostic role of T3/T4 ratio in metastatic renal cell carcinoma (mRCC): Preliminary results of the threeFOUR multicenter study (Meet-Uro 14) 149
New molecular therapies in patients with advanced Hepatocellular Cancer in second line of treatment: Is a real defeat?: Results from a literature based meta-analysis of randomized trials 148
An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC) 148
Gastric and colonic metastasis from NSCLC A very unusual case report 148
The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials 147
Clinical nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national survey on behalf of NutriOnc research group 146
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study 146
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review 145
Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis 145
In reply to Egger et al.: Lack of benefit from adjuvant postoperative radiotherapy and issues raised about upfront management of high- and very-high-risk prostate cancer patients 145
Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study 144
Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment 144
Acute Massive and Submassive Pulmonary Embolism: Preliminary Validation of Aspiration Mechanical Thrombectomy in Patients with Contraindications to Thrombolysis 144
Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials 144
Editorial: Microbiota and metabolites in cancer immunotherapy 143
Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients 143
Role of targeted agents in neuroendocrine tumors: Results from a meta-analysis 143
Evolution and emerging future of cytoreducxtive surgery and hyperthermic intraperitoneal chemoperfusion in gastric cancer: From treating the incurable to preventing recurrence 143
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 143
Totale 17.063
Salva come PNG Salva come JPEG
Categoria #
all - tutte 128.932
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 128.932
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021342 0 0 0 0 0 0 0 0 0 0 222 120
2021/20221.018 9 11 96 29 29 107 11 137 87 38 107 357
2022/20232.731 269 770 69 162 36 447 491 110 179 51 53 94
2023/20241.637 49 90 273 79 102 162 56 299 62 219 117 129
2024/202512.158 481 1.276 692 1.629 3.083 1.541 316 391 898 403 563 885
2025/202618.466 1.747 2.724 2.828 2.936 1.611 548 1.955 1.024 1.116 1.124 853 0
Totale 42.539